Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM Sees Extended Support For BIOSIM Act

Multiple US Organizations Come Together To Back Add-On Payment For Biosimilars

Executive Summary

US representatives Kurt Schrader and Adam Kinzinger have introduced the BIOSIM Act to improve access and realize the full potential of biosimilars by encouraging an additional payment for providers when they use a biosimilar cheaper than the reference biologic. AAM and a group of organizations have extended support to the bipartisan bill. 

You may also be interested in...



US Savings Top $338bn In 2020

Savings achieved in the US through the use of generics and biosimilars hit a new high in 2020, reaching $338bn, according to new figures released by the AAM.

Celltrion Sees Sales Dip In Q3

South Korea’s Celltrion delivered a relatively weak quarter in Q3, with a 26.9% drop in revenues despite robust sales of Truxima (rituximab) and Remsima (infliximab). The company also voiced confidence in pro-biosimilar policies introduced by the Biden administration in the US.

Indian Regulatory And Industry Bodies Call For Open Dialog With Policymakers

The Indian Pharmaceutical Alliance’s recent Global Innovation Summit 2021 saw regulatory and industry bodies call for policy intervention to provide support and incentives for innovation and R&D in the Indian pharmaceutical sector. Inaugurated by the Indian prime minister Narendra Modi, the summit saw Modi invite “everyone to ideate in India, innovate in India and make in India and make for the world.”

Topics

UsernamePublicRestriction

Register

GB151065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel